Natriuretic peptides and cardiovascular damage in the metabolic syndrome: Molecular mechanisms and clinical implications

Clinical Science

Volumn 118, Issue 4, 2010, Pages 231-240

  Savoia, Carmine ^a,b   Volpe, Massimo ^a   Alonzo, Alessandro ^a   Rossi, Chiara ^a   Rubattu, Speranza ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Cardiovascular disease; Metabolic syndrome; Natriuretic peptide; Obesity; Remodelling; Renin angiotensin system

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM ION; CYCLIC AMP; CYCLIC GMP; FATTY ACID; NATRIURETIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULITIS;

ADIPOSITY; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC SYNDROME X; NATRIURETIC PEPTIDES; OBESITY;

EID: 70549095151     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090204     Document Type: Review

References (110)

1. Dandona, P., Ajada, A., Chaudhuri, A., Mohanty, P. and Garg, R. (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 111, 1448-1454
2. Alberti, K. G. and Zimmet, P. Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classifications of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 15, 539-553
3. Grundy, S. M., Brewer, Jr, H. B., Cleeman, J. L., Smith, Jr, S. C. and Lenfant, C. (2004) Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American heart association conference on scientific issues related to definition. Circulation 109, 433-438
4. Einhorn, D., Reaven, G. M., Cobin, R. H., Ford, E., Ganda, O. P., Handelsman, Y., Hellman, R., Jellinger, P. S., Kendall, D., Krauss, R. M., Neufeld, N. D. et al. (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237-252
5. Alberti, K. G., Zimmet, P. and Shaw, J. (2005) IDF epidemiology task force consensus group. The metabolic syndrome-a new worldwide definition. Lancet 266, 1059-1062
6. Carr, D. B., Utzschneider, K. M., Hull, R. L., Kodama, K., Retzlaff, B. M., Brunzell, J. D., Shofer, J. B., Fish, B. E., Knopp, R. H. and Kahn, S. E. (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Educational Program Adult Panel III criteria for the metabolic syndrome. Diabetes 53, 2087-2094
7. Rubattu, S., Sciarretta, S., Valenti, V., Stanzione, R. and Volpe, M. (2008) Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am. J. Hypertens. 21, 733-741
8. Licata, G., Volpe, M., Scaglione, R. and Rubattu, S. (1994) Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23, I20-I24
9. Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Wilson, P.W. and Wasan, R. S. (2004) The impact of obesity on plasma natriuretic peptide levels: the Framinghan Heart Study. Circulation 109, 594-600
10. Goodfriend, T. L., Kelley, D. E., Goodpaster, B. H. and Winters, S. J. (1999) Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 7, 355-362
11. Savoia, C. and Schiffrin, E. L. (2004) Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Med. Clin. North Am. 88, 39-62
12. Koller, K. J. and Goeddel, D. V. (1992) Molecular biology of the natriuretic peptides and their receptors. Circulation 86, 1081-1088
13. Anand-Srivastava, M. B., Sairam, M. R. and Cantin, M. (1990) Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J. Biol. Chem. 265, 8566-8572
14. Maack, T., Tikonova, L. N., Friedman, O. and Cohen, D. (1996) Functional properties and dynamics of natriuretic peptide receptors. Proc. Soc. Exp. Biol. Med. 213, 109-116
15. Nakao, K., Sugawara, A., Morii, N., Sakamoto, M., Yamada, T., Itoh, H., Shiono, S., Saito, Y., Nishimura, K. and Ban, T. (1986) The pharmacokinetics of α-human atrial natriuretic polypeptide in healthy subjects. Eur. J. Clin. Pharmacol. 31, 101-103
16. Sengenes, C., Bouloumie, A., Hauner, H., Berlan, M., Busse, R., Lofantan, M. and Galitzky, J. (2003) Involvement of a cGMP-dependent pathway in a natriuretic peptide-mediated hormone sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem. 278, 48617-48626
17. Birkenfeld, A. L., Boschmann, M., Moro, C., Adams, F., Heusser, K., Franke, G., Berlan, M., Luft, F. C., Lafontan, M. and Jordan, J. (2005) Lipid mobilization with physiological atrial natriuretic peptide concentrations in human. J. Clin. Endocrinol. Metab. 90, 3622-3628
18. Moro, C., Galintzky, J., Sengenes, C., Crampes, F., Lafontan, M. and Berlan, M. (2004) Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther. 308, 984-992
19. Sengenes, C., Stich, V., Berlan, M., Hejnova, J., Lafontan, M., Pariskova, Z. and Galitzky, J. (2002) Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int. J. Obes. Relat. Metab. Disord. 26, 24-32
20. Moro, C., Crampes, F., Sengenes, C., De Glisezinski, I., Galitzky, J., Thalamas, C., Lafontan, M. and Berlan, M. (2004) Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J. 18, 908-910
21. Huss, J. M. and Kelly, D. P. (2004) Nuclear receptor signalling and cardiac energetics. Circ. Res. 95, 568-578
22. Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R., Valerio, A., Francolini, M., Moncada, S. and Carruba, M. O. (2003) Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299, 896-899
23. Pilz, S., Scharnagi, H., Tiran, B., Seelhorst, U., Wellnitz, B., Bohem, B. O., Schaefer, J. R. and März, W. (2006) Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J. Clin. Endocrinol. Metab. 91, 2542-2547
24. Bergman, R. N., Kim, S. P., Hsu, I. R., Catalano, K. J., Chiu, J. D., Kabir, M., Richey, J. M. and Ader, M. (2007) Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med. 120, S3-S8
25. Despres, J. P. and Lemieux, I. (2006) Abdominal obesity and metabolic syndrome. Nature 444, 881-887
26. Navab, M., Anantharamaiah, G. M. and Fogelman, A. M. (2005) The role of high density lipoprotein in inflammation. Trends Cardiovasc. Med. 15, 158-161
27. Sarzani, R., Marcucci, P., Salvi, F., Bordicchia, M., Espinosa, E., Mucci, L., Lorenzetti, B., Minardi, D., Muzzonigro, G., Dessì-Fulgheri, P. and Rappelli, A. (2008) Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int. J. Obes. 32, 259-267
28. Sarzani, R., Dessi-Fulgheri, P., Paci, M. V., Espinosa, E. and Rappelli, A. (1996) Expression of natriuretic peptides receptors in human adipose tissues. J. Endocrinol. Invest. 19, 581-585
29. Dessi-Fulgheri, P., Sarzani, R., Tamburrini, P., Moraca, A., Espinosa, E., Cola, G., Giantomassi, L. and Rappelli, A. (1997) Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J. Hypertens. 15, 1696-1699
30. Sarzani, R., Paci, M. V., Zingareti, C. M., Pierleoni, C., Cinti, S., Cola, G., Rappelli, A. and Dessì-Fulgheri, P. (1995) Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J. Hypertens. 13, 1241-1246
31. Dessì-Fulgheri, P., Sarzani, R., Serenelli, M., Tamburrini, P., Spagnolo, D., Giantomassi, L., Espinosa, E. and Rappelli, A. (1999) Low calorie diet enhances renal, hemodynamic and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension 33, 658-662
32. Das, S. R., Drazner, M. H., Dries, D. L., Vega, G. L., Stanek, H. G., Abdullah, S. M., Canham, R. M., Chung, A. K., Leonard, D., Wians, Jr, F. H. and De Lemos, J. A. (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112, 2163-2068
33. Mehra, M. R., Uber, P. A., Park, M. H., Scott, R. L., Ventura, H. O., Harris, B. C. and Fronlich, E. D. (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. J. Am. Coll. Cardiol. 43, 1590-1595
34. Wang, T. J., Larson, M. G., Keyes, M. J., Levy, D., Benjamin, E. L. and Vasan, R. S. (2007) Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115, 1345-1353
35. Olsen, M. H., Hansen, T.W., Christensen, M. K., Gustafsson, F., Rasmussen, S., Watchell, K., Borch-Johnsen, K., Ibsen, H., Jorgensen, T. and Hildebrandt, P. (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46, 660-666
36. Hall, C. (2004) Essential biochemistry and physiology of (NT-pro)BNP. (2004) Eur. J. Heart Failure 6, 257-260
37. Johnston, C. I., Hodsman, P. G., Kohzuki, M., Casley, D. J., Fabris, B. and Phillips, P. A. (1989) Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system: endogenous antagonists. Am. J. Med. 87, 24S-28S
38. Velloso, L. A., Folli, F., Sun, X. J., White, M. F., Saad, M. J. and Kahn, C. R. (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. U.S.A. 93, 12490-12495
39. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K. and Harrison, D. G. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923
40. Fliser, D., Buchholz, K. and Haller, H. (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110, 1103-1107
41. Janke, J., Engeli, S., Gorzelniak, K., Luft, F. C. and Sharma, A. M. (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51, 1699-1707
42. Henriksen, E. J. and Jacob, S. (2003) Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes. Metab. 5, 214-222
43. Carlsson, P. O., Berne, C. and Jansson, L. (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41, 127-133
44. Uehlinger, D. E.,Weidmann, P., Gnadinger, M. P., Hasler, L., Bachmann, C., Shaw, S., Hellmuller, B. and Lang, R. E. (1986) Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J. Cardiovasc. Pharmacol. 8, 1122-1129
45. Verspohl, E. J. and Bernemann, I. K. (1996) Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets. Peptides 17, 1023-1029
46. Tsukagoshi, H., Shimizu, Y., Kawata, T., Hisada, T., Shimitzu, Y., Iwamae, S., Ishizuka, T., Izuka, K., Dobashi, K. and Mori, M. (2001) Atrial natriuretic peptide inhibits tumor necrosis factor-α production by interferon-γ-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-κ B activation. Regul. Pept. 99, 21-29
47. Kiemer, A. K., Lehner, M. D., Hartung, T. and Vollmar, A. M. (2002) Inhibition of cyclooxygenase-2 by natriuretic peptides. Endocrinology 143, 846-852
48. Weber, N. C., Blumenthal, S. B., Hartung, T., Vollmar, A. M. and Kiemer, A. K. (2003) ANP inhibits TNF-α-induced endothelial MCP-1 expression: involvement of p38 MAPK and MKP-1. J. Leukocyte Biol. 74, 932-941
49. Moro, C., Klimcakova, E., Lolmede, K., Berlan, M., Lafontan, M., Stich, V., Bouloumié, A., Galitzky, J., Arner, P. and Langin, D. (2007) Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50, 1038-1047
50. Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A. and Hildebrandt, P. (2005) Plasma adiponectin, body mass index and mortality in patients with chronic heart failure. Circulation 112, 1756-1762
51. Bergandi, L., Silvagno, F., Russo, I., Riganti, C., Anfossi, G., Aldieri, E., Ghigo, D., Trovati, M. and Bosia, A. (2003) Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23, 2215-2221
52. Leoncini, G., Ratto, E., Viazzi, F., Vaccaro, V., Parodi, D., Parodi, A., Falqui, V., Tomolillo, C., Deferrari, G. and Pontremoli, R. (2005) Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med. 257, 454-460
53. Steinhelper, M. E., Cochrane, K. L. and Field, L. J. (1990) Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 16, 301-307
54. Ogawa, Y., Itoh, H., Tamura, N., Suga, S., Yoshimasa, T., Uehira, M., Matsuda, S., Shiono, S., Nishimoto, H. and Nakao, K. (1994) Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene J. Clin. Invest. 93, 1911-1921
55. Jhon, S.W. M., Krege, J. H., Oliver, P. M., Hagaman, J. R., Hodgin, J. B., Pang, S., Flynn, T. G. and Smithies, O. (1995) Genetic decreases in atrial natriuretic peptide and salt sensitive hypertension. Science 267, 679-681
56. Lopez, M. J., Wong, S. K., Kishimoto, I., Dubois, S., Mach, V., Friesen, J., Garbers, D. L. and Beuve, A. (1995) Salt-resistant hypertension in mice lacking the guanyl cyclase-A receptor for atrial natriuretic peptide. Nature 378, 65-68
57. Rubattu, S., Evangelista, A., Barbato, D., Barba, G., Stanzione, R., Iacone, R., Volpe, M. and Strazzullo, P. (2007) Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. J. Hum. Hypertens. 21, 822-824
58. Dora, K. A., Garland, C. J., Kwan, H. Y. and Yao, X. (2001) Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel. Am. J. Physiol. Heart Circ. Physiol. 280, H1272-H1277
59. Rosado, J. A., Porras, T., Conde, M. and Sage, S. O. (2001) Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein tyrosine phosphorylation and altered actin polymerization in human platelets. J. Biol. Chem. 276, 15666-15675
60. Geiger, J., Nolte, C., Butt, E., Sage, S. O. and Walter, U. (1992) Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc. Natl. Acad. Sci. U.S.A. 89, 1031-1035
61. D'Souza, S. P., Davis, M. and Baxter, G. F. (2004) Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol. Ther. 101, 113-129
62. Whalin, M. E., Scammell, J. G., Strada, S. J. and Thompson, W.J. (1991) Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells. Mol. Pharmacol. 39, 711-717
63. Chauhan, S. D., Nilsson, H., Ahluwalia, A. and Hobbs, A. J. (2003) Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc. Natl. Acad. Sci. U.S.A. 100, 1426-1431
64. Volpe, M., Cuocolo, A., Vecchione, F., Lembo, G., Pignalosa, S., Condorelli, M. and Trimarco, B. (1989) Influence of volume expansion on hemodynamic effects of atrial natriuretic factor in rabbits. Am. J. Physiol. 256, H852-H858
65. Volpe, M., Lembo, G., Condorelli, G. L., De Luca, N., Lamenza, F., Indolfi, C. and Trimarco, B. (1990) Converting enzyme inhibition prevents the effect of atrial natriuretic factor on baroreflex responses in humans. Circulation 82, 1214-1221
66. Volpe, M., De Luca, N., Cappelli-Bigazzi, M., Vecchione, F., Lembo, G., Condorelli, M. and Trimarco, B. (1988) Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man. Circulation 77, 849-855
67. Schultz, H. D., Gardner, D. G., Deschepper, C. F., Coleridge, H. M. and Coleridge, J. C. (1988) Vagal C fibre blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am. J. Physiol. 155, R6-R13
68. Yang, R. H., Jin, H. K., Wyss, J. M., Chen, Y. F. and Oparil, S. (1992) Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitari. Hypertension 19, 198-205
69. Saper, C. B., Standaert, D. G., Currie, M. G., Schwartz, D., Geller, D. M. and Needleman, P. (1985) Atriopeptin immunoreactive neurons in the brain: presence in cardiovascular regulatory areas. Science 227, 1047-1049
70. Aneja, A., El-Atat, F., McFarlane, S. I. and Sowers, J. R. (2004) Hypertension and obesity. Recent Progr. Horm. Res. 59, 169-205
71. Mancia, G., Bousquet, P., Elghozi, J. L., Esler, M., Grassi, G., Julius, S., Reid, J. and van Zwieten, P. A. (2007) The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 25, 909-920
72. Serazin, V., Dos Santos, E., Morot, M. and Giudicelli, Y. (2004) Human adipose angiotensinogen gene expression and secretion are stimulated by cyclic AMP via increased DNA cyclic AMP responsive element binding activity. Endocrine 25, 97-104
73. Barbato, E., Rubattu, S., Bartunek, J., Berni, A., Sarno, G., Vanderheyden, M., Delrue, L., Zardi, D., Pace, B., De Bruyne, B. et al. (2009) Human coronary atherosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis, doi:10.1016/ j.atherosclerosis.2009.01.033
74. Itoh, H., Pratt, R. E. and Dzau, V. J. (1990) Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J. Clin. Invest. 86, 1690-1697
75. Furuya, M., Aisaka, K., Miyazaki, T., Honbou, N., Kawashima, K., Ohno, T., Tanaka, S., Minamino, N., Kangawa, K. and Matsuo, H. (1993) C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 193, 248-253
76. Schirger, J. A., Grantham, J. A., Kullo, I. J., Jougasaki, M., Wennberg, P. W., Chen, H. H., Lisy, O., Miller, V., Simari, R. D. and Burnett, Jr, J. C. (2000) Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J. Am. Coll. Cardiol. 35, 796-801
77. Kiemer, A. K. and Vollmar, A. M. (1998) Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J. Biol. Chem. 273, 13444-13451
78. Kiemer, A. K., Weber, N. C. and Vollmar, A. M. (2002) Induction of IκB: atrial natriuretic peptide as a regulator of the NF-κB pathway. Biochem. Biophys. Res. Commun. 295, 1068-1076
79. Kapoun, A. M., Liang, F., O'young, G., Damm, D. L., Quon, D., White, R. T., Munson, K., Lam, A., Schreiner, G. F. and Protter, A. A. (2004) B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94, 453-461
80. Horio, T., Tokudome, T., Maki, T., Yoshihara, F., Suga, S., Nishikimi, T., Kojima, M., Kawano, Y. and Kangawa, K. (2003) Gene expression, secretion and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 144, 2279-2284
81. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Mikishima, M., Matsuda, M. and Shimomura, I. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752-1761
82. Maahs, D. M., Ogden, L. G.,Kinney, G. L., Wadwa, P., Snell-Bergeon, J. K., Dabelea, D., Hokanson, J. E., Ehrlich, J., Eckel, R. H. and Rewers, M. (2005) Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111, 747-753
83. Kathiresan, S., Gona, P., Larson, M. G., Vita, J. A., Mitchell, G. F., Tofler, G. H., Levy, D., Newton-Cheh, C., Wang, T. J., Benjamin, E. J. and Vasan, R. S. (2006) Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 113, 938-945
84. Kooh, H., Itoh, H., Choi, B. S., Sawada, N., Doi, K., Hwang, T. J., Kim, K. K.,Arai,H., Baik, Y. H. and Nakao, K. (2003) Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am. J. Physiol. Heart Circ. Physiol. 284, H1388-H1397
85. Supaporn, T., Wennberg, P. W., Wei, C. M., Kinoshita, M., Matsuda, Y. and Burnett, Jr, J. C. (1996) Role of the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin. Sci. 90, 357-362
86. Kasama, S., Toyama, T., Hatori, T., Sumino, H., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T. and Kurabayashi, M. (2007) Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J. Am. Coll. Cardiol. 49, 667-674
87. Okumura, K., Yasue H., Fujii H., Kugiyama, K., Matsuyama, K., Yoshimura, M., Jougasaki, M., Kikuta, K., Kato, H. and Tanaka, H. (1995) Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: comparison with effects of systemic hemodynamic variables. J. Am. Coll. Cardiol. 25, 342-348
88. Wei, C. M., Hu, S., Miller, V. M. and Burnett, Jr, J. C. (1994) Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 205, 765-771
89. Wiley, K. E. and Davenport, A. P. (2001) Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br. J. Pharmacol. 133, 568-574
90. Toth, M., Vuorinen, K. H., Vuoltheenaho, O., Hassinen, I. E., Uusimaa, P. A., Leppaluoto, J. and Ruskoaho, H. (1994) Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am. J. Physiol. 266, H1572-H1580
91. ATP channel opening. Am. J. Physiol. Heart Circ. Physiol. 284, H1592-H1600
92. Hong, S. N., Ahn, Y., Yoon, N. S., Moon, J. Y., Kim, K. H., Hong, Y. J., Park, H. W., Kim, J. H., Jeong, M. H., Cho, J. C. et al. (2008) N-terminal pro-B-tye natriuretic peptide level is depressed in patients with significant coronary artery disease who have high body mass index. Int. Heart J. 49, 403-412
93. Berger, R., Huelsman, M., Strecker K., Bojic, A., Moser, P., Stanek, B. and Pacher, R. (2002) B-type natriuretic peptides predicts sudden death in patients with chronic heart failure. Circulation 105, 2392-2397
94. Nishikimi, T., Yoshihara, F., Morimoto, A., Ishikawa, K., Ishimitsu, T., Saito, Y., Kangawa, K., Matsuo, H., Omae, T. and Matsuoka, H. (1996) Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28, 22-30
95. Hayashi, D., Kudoh, S., Shiojima, I., Zou, Y., Harada, K., Shimoyama, M., Imai, Y., Monzen, K., Yamazaki, T., Yazaki, Y. et al. (2004) Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase posphatase-1. Biochem. Biophys. Res. Commun. 322, 310-319
96. Calderone, A., Thaik, C. M., Takahashi, N., Chang, D. L. and Colucci, W. S. (1998) Nitric oxide, atrial natriuretic peptide, and cyclic cGMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101, 812-818
97. Laskowski, A., Woodman, O. L., Cao, A. H., Drummond, G. R., Marshall, T., Kaye, D. M. and Ritchie, R. H. (2006) Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc. Res. 72, 112-123
98. Rubattu, S., Bigatti, G., Evangelista, A., Lanzani, C., Stanzione, R., Zagato, L., Manunta, P., Marchitti, S., Venturelli, V., Bianchi, G. et al. (2006) Association of atrial natriuretic peptide and type-A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J. Am. Coll. Cardiol. 48, 499-505
99. Rubattu, S., Sciarretta, S., Ciavarella, G. M., Venturelli, V., De Paolis, P., Tocci, G., De Biase, L., Ferrucci, A. and Volpe, M. (2007) Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J. Hypertens. 25, 833-839
100. Molkentin, J. D. (2003) A friend within the heart: natriuretic peptide receptor signaling. J. Clin. Invest. 111, 1275-1277
101. Jones, E. C., Devereux, R. B., O'Grady, M. J., Schwartz, J. E., Liu, J. E., Pickering, T. G. and Roman, M. J. (1997) Relation of hemodynamic volume load to arterial and cardiac size. J. Am. Coll. Cardiol. 29, 1303-1310
102. Cuspidi, C., Meani, S., Fusi, V., Severgnini, B., Valerio, C., Catini, E., Sala, C., Sampieri, L., Magrini, F. and Zanchetti, A. (2004) Metabolic syndrome and target organ damage in untreated essential hypertensives. J. Hypertens. 22, 1991-1998
103. Schillaci, G., Pirro, M., Pucci, G., Mannarino, M. R., Gemelli, F., Siepi, D., Vaudo, G. and Mannarino, E. (2006) Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 47, 881-886
104. Lind, L., Andersson, P. E., Andren, B., Hanni, A. and Lithell, H. O. (1995) Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J. Hypertens. 13, 433-438
105. Horio, T., Nishikimi, T., Yoshihara, F., Matsuo, P., Takishita, S. and Kangawa, K. (2000) Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35, 19-24
106. Sagnella, G. A. (2001) Atrial natriuretic peptide mimetics and vasopeptidase inhibitors. Cardiovasc. Res. 51, 416-428
107. Mitchell, G. F., Izzo, J. L., Lacourcière, Y., Ouellet, J. P., Neutel, J., Qian, C., Kerwin, L. J., Block, A. J. and Pfeffer, M. A. (2002) Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension. Results of the Conduit Hemodynamics of Omapatrilat International Research study. Circulation 105, 2955-2961
108. Corti, R., Burnett, J. C., Rouleau, J. L., Ruschitzka, F. and Lüscher, T. F. (2001) Vasopeptidase inhibitors. A new therapeutic concept in cardiovascular disease? Circulation 104, 1856-1862
109. Campbell, D. J. (2001) Vasopeptidase inhibition. A double-edged sword? Hypertension 41, 383-389
110. Woodard, G. E. and Rosado, J. A. (2008) Natriuretic peptides in vascular physiology and pathology. Int. Rev. Cell. Mol. Biol. 268, 59-93